Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Afuresertib |
Trade Name | |
Synonyms | GSK2110183|GSK-2110183 |
Drug Descriptions |
Afuresertib (GSK2110183) is a pan-AKT, ATP-competitive inhibitor, which may result in inhibition of the PI3K/AKT signaling pathway and tumor cell proliferation, and induction of tumor cell apoptosis (PMID: 25075128, PMID: 30563934). |
DrugClasses | Akt Inhibitor (Pan) 21 AKT Inhibitor (Pan) - ATP competitive 7 |
CAS Registry Number | 1047644-62-1 |
NCIT ID | C82390 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Afuresertib | Afuresertib | 1 | 3 |
Afuresertib + Carboplatin + Paclitaxel | Afuresertib Carboplatin Paclitaxel | 0 | 0 |
Afuresertib + Carfilzomib | Afuresertib Carfilzomib | 0 | 1 |
Afuresertib + Fulvestrant | Afuresertib Fulvestrant | 0 | 1 |
Afuresertib + LAE001 + Prednisone | Afuresertib LAE001 Prednisone | 0 | 1 |
Afuresertib + Ofatumumab | Afuresertib Ofatumumab | 0 | 1 |
Afuresertib + Paclitaxel | Afuresertib Paclitaxel | 0 | 1 |
Afuresertib + Trametinib | Afuresertib Trametinib | 0 | 0 |